Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Venous Pulmonary Waveforms in MitraClip Have Prognostic Value

Courtesy of Dr. Carlos Fava.

The MitraClip has been shown to benefit a certain group of patients and it is a well-known fact that a ≥5 mmHg is associated to a more torpid evolution. However, there is little evidence when it comes to venous pulmonary waves, changes in left atrial pressure and V wave.

121 patients with severe mitral regurgitation receiving MitraClip were retrospectively analyzed.

Mean age was 76, over 50% were men, 25% were diabetic, most were in functional class III-IV, 60% had atrial fibrillation and 43% ejection fraction.

The cause was degenerative in 64% of cases.

The number of implanted clips was 1.5, and it brought significant reduction of mitral regurgitation. Mortality was 8% with a low rate of complications.


Read also: Hours of Sleep and Myocardial Infarction Risk.


There was an increase in transmitral gradient (2.1 mmHg to 3.6 mmHg p <0.001) and in addition there was a reduction of left atrial pressure (23 mmHg to 19 mmHg p<0.001) and V wave (43 mmHg vs. 28 mmHg p<0.001). There was also improved S wave velocity after MictraClip.

Survival at 24 months was in favor of patients with improved pulmonary venous waves (85% vs. 40% p<0.001), all-cause mortality, and the composite of all cause death, need of left atrial assistance, reintervention, valve surgery and rehospitalization for cardiac failure.

Conclusion

Pulmonary venous waveforms are an important success marker after percutaneous mitral repair. These data chow that venous pulmonary waveforms might predict rehospitalization and mortality after percutaneous mitral repair. Large multicenter studies are called for to shed light on this matter.

Courtesy of Dr. Carlos Fava.

Original Title: Pulmonary Venous Waveforms Predict Rehospitalization and Mortality After Percutaneous Mitral Valve Repair.

Reference: Frank E. Corrigan, et al. JACC Cardiovsc Imag.DOI: 10.1016/j.jcmg.2018.07.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...